Difference between revisions of "Marginal zone lymphoma - historical"
Jump to navigation
Jump to search
m |
|||
| Line 26: | Line 26: | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
| − | *[[Umbralisib (Ukoniq)]] 800 mg PO once per day | + | *[[Umbralisib (Ukoniq)]] 800 mg PO once per day on days 1 to 28, with food |
| − | ''' | + | '''28-day cycles''' |
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
<!-- #'''Abstract:''' Nathan Hale Fowler, Felipe Samaniego, Wojciech Jurczak, Ewa Lech-Maranda, Nilanjan Ghosh, Piers Patten, James Andrew Reeves, Lori Ann Leslie, Julio C. Chavez, Paolo Ghia, Corrado Tarella, John M. Burke, Jeff Porter Sharman, Kathryn Kolibaba, Owen A. O'Connor, Chan Cheah, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, and Pier Luigi Zinzani. Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study. Journal of Clinical Oncology 2019 37:15_suppl, 7506-7506 [https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.7506 link to abstract] --> | <!-- #'''Abstract:''' Nathan Hale Fowler, Felipe Samaniego, Wojciech Jurczak, Ewa Lech-Maranda, Nilanjan Ghosh, Piers Patten, James Andrew Reeves, Lori Ann Leslie, Julio C. Chavez, Paolo Ghia, Corrado Tarella, John M. Burke, Jeff Porter Sharman, Kathryn Kolibaba, Owen A. O'Connor, Chan Cheah, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, and Pier Luigi Zinzani. Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study. Journal of Clinical Oncology 2019 37:15_suppl, 7506-7506 [https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.7506 link to abstract] --> | ||
| − | #'''UNITY-NHL:''' Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, Knopińska-Posłuszny W, Cheah CY, Phillips T, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca G, Babu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, Miskin HP, Sportelli P, O'Connor OA, Weiss MS, Zinzani PL. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2021 May 20;39(15):1609-1618. Epub 2021 Mar 8. [https://doi.org/10.1200/jco.20.03433 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8148421/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33683917/ PubMed] [https://clinicaltrials.gov/study/NCT02793583 NCT02793583] | + | #'''UNITY-NHL:''' Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, Knopińska-Posłuszny W, Cheah CY, Phillips T, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca G, Babu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, Miskin HP, Sportelli P, O'Connor OA, Weiss MS, Zinzani PL. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2021 May 20;39(15):1609-1618. Epub 2021 Mar 8. [https://doi.org/10.1200/jco.20.03433 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8148421/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/33683917/ PubMed] [https://clinicaltrials.gov/study/NCT02793583 NCT02793583] |
[[Category:Marginal zone lymphoma regimens]] | [[Category:Marginal zone lymphoma regimens]] | ||
Revision as of 14:10, 5 November 2023
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? Please go to the main MZL regimen page to find other regimens.
1 regimens on this page
1 variants on this page
|
Relapsed or refractory
Umbralisib monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Fowler et al. 2021 (UNITY-NHL) | 2017-2018 | Phase 2b (RT) |
Targeted therapy
- Umbralisib (Ukoniq) 800 mg PO once per day on days 1 to 28, with food
28-day cycles
References
- UNITY-NHL: Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, Knopińska-Posłuszny W, Cheah CY, Phillips T, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca G, Babu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, Miskin HP, Sportelli P, O'Connor OA, Weiss MS, Zinzani PL. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2021 May 20;39(15):1609-1618. Epub 2021 Mar 8. link to original article link to PMC article contains dosing details in manuscript PubMed NCT02793583